Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Semaglutide injections effectively support weight loss by regulating appetite and glucose levels, offering benefits for ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

In the heavyweight title match between weight loss meds, we have ourselves a victor.In the battle between Novo Nordisk’s ...

The study concentrates on the FDA-approved injectable medications semaglutide and liraglutide. A study conducted by the ...

Healthcare firms have done comparatively well in an otherwise subdued U.S. IPO market in 2024, which analysts touted as a comeback year for public offerings. The Richmond, California-based company ...

U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...

Finding semaglutide could benefit sufferers of condition that causes abscesses and scarring on the skin described as 'highly ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.